One aspect of the AIDS pandemic which has provoked considerable media interest and concern is the development and spread of multiple drug resistant tuberculosis particularly, but not exclusively, in the USA. Individuals infected with HIV have increased susceptibility to tuberculosis acquired both de novo'2 and by reactivation of latent infection. 3 The emergence of drug resistant organisms seems to have arisen because of poor compliance with antituberculosis therapy, particularly in some subgroups such as intravenous drug users and alcoholics,4-6 and by reactivation of disease in immigrants from countries with high rates of both tuberculosis5 and drug resistance. 5 1983 , and 1988. In 1978-9's 1 -6% of previously untreated white patients and 7-5% of patients from the Indian subcontinent had primary drug resistance. In 198319 these figures were 1-7% and 13 1% respectively, and in 198820 the rate in white patients was 2-3% but in patients from the Indian subcontinent it had fallen to 4-7% in previously untreated cases. Longitudinal data from a high incidence area of the UK21 22 from 1960-89 show a progressive decline in primary and acquired drug resistance in white patients, no progressive increase in primary or acquired drug resistance in the cases from the Indian subcontinent, and no evidence of cross infection between the two ethnic groups.
While the low rates of primary resistance in the UK are encouraging, there are no grounds for complacency. Drug resistance rates, both primary and in patients with a history of previous treatment, remain very high in patients from the Indian subcontinent. Recent studies have shown primary resistance rates to isoniazid of 14%, and acquired resistance rates of 37% to rifampicin and 55% to isoniazid in India,2' and 17e7% resistance to isoniazid in Pakistan. 24 Patients from the Indian subcontinent now account for 39% of tuberculosis cases in England and Wales.20 Whether the falling proportion of drug resistance in this ethnic group2O continues will depend partly on the level of continuing immigration, and on the resistance characteristics of any clinical tuberculosis developing in those immigrants. It will also partly depend on the extent to which tuberculosis develops in persons born or settled in the UK following visits to the Indian subcontinent. This has been shown to be a risk factor in up to 20% of cases of tuberculosis. 25 The treatment of drug resistant tuberculosis should follow the general principle of using at least three drugs not previously used in the patient and to which the organism is sensitive until cultures become negative,26 followed by a minimum of two drugs for a further period, preferably with fully supervised medication to ensure compliance. This can be difficult initially because of the time delays in the isolation and drug sensitivity testing of mycobacteria which can take several weeks, and because of the reduced availability of effective drugs with which to treat the infection. As a result of these difficulties considerable effort is now being applied on two fronts. Firstly, new drug regimens and combinations are being tested which may include rifabutin,27 the newer macrolide antibiotics azithromycin and clarithromycin, and/or fluoroquinolones. Treatment, however, remains difficult and may only give response rates of the order of 50%, with a high death rate often with persistently positive cultures.28 Because of this an alternative form of treatment using immunotherapy with heat killed Mycobacterium vaccae has been proposed with some limited success. 29 Secondly, the delays in isolation and sensitivity testing of bacteria, during which time drug treatment could be inadequate allowing further resistance to emerge, has given an urgent impetus to rapid methods of diagnosis. These are mainly through identifying specific genetic material by such techniques as the polymerase chain reaction3032 and restriction fragment length poly-
The tuberculosis control system in the UK is different from that in the USA and is a major reason why the problems of multiple drug resistant tuberculosis have not so far arisen. Clinical care, particularly for pulmonary disease, is largely but not exclusively provided by thoracic physicians who have training in the management of tuberculosis. As the number of cases in the UK has fallen clinical expertise has reduced and is now most concentrated in areas with urban deprivation, or significant ethnic minority populations, or both. 
